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Abstract
Introduction: Women who carry a BRCA1 mutation typically develop “triple-negative” breast cancers (TNBC),
defined by the absence of estrogen receptor (ER), progesterone receptor and Her2/neu. In contrast to ER-positive
tumors, TNBCs frequently express high levels of epidermal growth factor receptor (EGFR). Previously, we found a
disproportionate fraction of progenitor cells in BRCA1 mutation carriers with EGFR overexpression. Here we
examine the role of EGFR in mammary epithelial cells (MECs) in the emergence of BRCA1-related tumors and as a
potential target for the prevention of TNBC.
Methods: Cultures of MECs were used to examine EGFR protein levels and promoter activity in response to BRCA1
suppression with inhibitory RNA. EGFR was assessed by immunoblot and immunofluorescence analysis, real-time
reverse transcriptase-polymerase chain reaction assay (RT-PCR) and flow cytometry. Binding of epidermal growth
factor (EGF) to subpopulations of MECs was examined by Scatchard analysis. The responsiveness of MECs to the
EGFR inhibitor erlotinib was assessed in vitro in three-dimensional cultures and in vivo. Mouse mammary tumor
virus-Cre recombinase (MMTV-Cre) BRCA1
flox/flox p53
+/- mice were treated daily with erlotinib or vehicle control, and
breast cancer-free survival was analyzed using the Kaplan-Meier method.
Results: Inhibition of BRCA1 in MECs led to upregulation of EGFR with an inverse correlation of BRCA1 with cellular
EGFR protein levels (r
2 = 0.87) and to an increase in cell surface-expressed EGFR. EGFR upregulation in response to
BRCA1 suppression was mediated by transcriptional and posttranslational mechanisms. Aldehyde dehydrogenase 1
(ALDH1)-positive MECs expressed higher levels of EGFR than ALDH1-negative MECs and were expanded two- to
threefold in the BRCA1-inhibited MEC population. All MECs were exquisitely sensitive to EGFR inhibition with
erlotinib in vitro. EGFR inhibition in MMTV-Cre BRCA1
flox/flox p53
+/- female mice starting at age 3 months increased
disease-free survival from 256 days in the controls to 365 days in the erlotinib-treated cohort.
Conclusions: We propose that even partial loss of BRCA1 leads to an overall increase in EGFR expression in MECs
and to an expansion of the highly EGFR-expressing, ALDH1-positive fraction. Increased EGFR expression may confer
a growth advantage to MECs with loss of BRCA1 at the earliest stages of transformation. Employing EGFR inhibition
with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast
tumors in this mouse model.
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Primary prevention of breast cancer has traditionally
centered on estrogen receptor (ER) blockade, largely
because the vast majority of breast cancers express ER
and because ER antagonists are both easily administered
and well-tolerated. However, ER antagonists do not pre-
vent the most aggressive form of breast cancer: tumors
that are ER- and progesterone (PR)-negative [1]. These
tumors account for 15% to 20% of all breast cancers,
occur with disproportionately high frequency in African-
Americans and carry the worst prognosis [2,3]. The sub-
group of women who are at highest risk for ER- and
PR-negative breast cancers are women who carry a
germline mutation in BRCA1. These women typically
develop “triple-negative” breast cancers (TNBCs), which
are defined by the absence of ER, PR and Her2 expres-
s i o na n da r et h o u g h tt ob ec a u s e db yg e n e t i ci n s t a b i l i t y
that results from a germline mutation in BRCA1 [4].
Though nominally classified as a diagnosis of exclu-
sion (thus “triple-negative”), TNBC tumors frequently
(72-75%) [5] overexpress epidermal growth factor recep-
t o r( E G F R ) ,w h e r e a so n l yam i n o r i t y( 1 6 % )o fE R -
positive breast cancers overexpress EGFR [5,6]. The
high frequency of EGFR expression in TNBCs suggests
that loss of BRCA1 may be coupled, either directly or
indirectly, with EGFR overexpression in breast cancer
[6]. This connection is further supported by the finding
that sporadic TNBCs frequently exhibit both epigenetic
silencing of BRCA1 [7] and overexpression of EGFR [5].
However, how TNBCs enrich for tumor cells with high
EGFR expression is unknown.
Previously, we examined the proliferation and differ-
entiation properties of BRCA1-mutant primary human
MECs (hMECs) [8] and found a disproportionate frac-
tion of progenitor cells in BRCA1 mutation carriers with
concomitant EGFR overexpression and absence of ERa.
Here we report that inhibition of BRCA1 in MECs leads
to the upregulation of EGFR and the expansion of an
aldehyde dehydrogenase 1 (ALDH1)-positive mammary
epithelial progenitor cell population. We show that
these MECs are exquisitely sensitive to EGFR inhibition
with erlotinib and that EGFR inhibition in vivo could
prevent the emergence of TNBCs.
Materials and methods
Reagents
Phycoerythrin (PE)-conjugated mouse anti-EGFR anti-
body (EGFR.1, 555997), PE-conjugated mouse immuno-
globulin G2b (IgG2b) isotype control antibody (27-35;
555744) were obtained from BD Biosciences, San Diego,
CA, USA, and QuantiBrite beads (340495) were
obtained from BD Biosciences, San Jose, CA, USA. The
ALDEFLUOR assay kit was purchased from STEMCELL
Technologies, Durham, NC, USA. Rhodamine (Rh)-EGF
(E-3481) was purchased from Invitrogen, Carlsbad, CA,
USA. For immunofluorescence analysis, we used a
mouse anti-EGFR antibody (EGFR.1, 555997) obtained
from BD Biosciences, San Diego, CA, USA. For immu-
nohistochemical analysis, we used anti-EGFR antibody
(ab52894, rabbit monoclonal antibody EP38Y; Abcam,
Cambridge, MA, USA), anti-ALDH1A1 antibody
(ab52492, rabbit monoclonal antibody, EP1933Y;
Abcam, Cambridge, MA, USA), anti-cleaved caspase 3
antibody (9661S, rabbit polyclonal antibody, Asp175;
Cell Signaling Technology, Danvers, MA, USA), anti-
Ki-67 antibody (9106-S, rabbit monoclonal antibody
SP6; ThermoScientific, Fremont, CA, USA) and mouse
anti-ERa antibody (MC-20, SC-524; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). For immunoblot analysis,
mouse anti-BRCA1 antibody (MS110) was purchased
from Calbiochem (manufactured by EMD Biosciences
Inc., San Diego, CA, USA). Erlotinib was purchased
from LC Laboratories (Woburn, MA, USA).
Cell culture
Informed consent was obtained for the collection of pri-
mary hMECs from mastectomy specimens of BRCA1
mutation carriers (DFHCC-IRB legacy 04-405), and cells
were isolated as described previously [8]. MECs were
cultured in Mammary Epithelial Cell Growth Medium
(MEGM; Lonza, Walkersville, MD, USA) or HuMEC
medium (Gibco, Invitrogen, Carlsbad, CA, USA) supple-
mented with bovine pituitary extract. MCF-10A human
epithelial cells (American Type Culture Collection
(ATCC), Manassas, VA, USA), hMEC-expressing human
telomerase reverse transcriptase (hTERT) cells and
immortalized human mammary epithelial cells (HMLE
cells) (gift from Dr. Robert Weinberg) were cultured in
a mixture of Dulbecco’s modified Eagle’s medium-Ham’s
F-12 medium supplemented with 5% horse serum,
20 ng/ml EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml
cholera toxin and 10 μg/ml insulin. MCF-7 cells, the
HCC1937 BRCA1-mutant breast cancer cell line
(ATCC) and HCC1937 cells stably transfected with
green fluorescent protein (GFP)-BRCA1 (gift from
Dr. Ralph Scully) were kept in RPMI 1640 medium with
10% fetal bovine serum. For three-dimensional cultures,
the cells were embedded in 40 μl of Geltrex (Invitrogen,
C a r l s b a d ,C A ,U S A )a n dc u l t u r e di ne i g h t - c h a m b e rc u l -
ture slides (BD Falcon, San Diego, CA, USA).
Cell viability and luciferase assays
For cell viability assays, MECs were seeded at a density
of 250 cells/well in 96-well plates, and cell viability was
determined using the CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI, USA) according
to the manufacturer’s instructions, and absorption was
read using a Wallac 3 plate reader. For luciferase assays,
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on day 1, transfected with BRCA1 small interfering
RNA 1 (BRCA1 si1) or small interfering RNA 2 (BRCA1
si2) or control small interfering RNA (siRNA) on day 2
and with control or the full-length EGFR luciferase con-
struct on day 3, followed by a luciferase assay performed
on day 4. For each experiment, 2 μg of reporter con-
struct were transfected in combination with either 1 ng
of hMEC or 10 ng of Renilla thymidine kinase (Renilla
TK) (MCF-7), and luciferase activity was determined
using a Wallac 3 plate reader.
Plasmids and inhibitory RNA constructs
The full-length EGFR promoter inserted 5’ from a luci-
ferase reporter [9] was a gift from Drs. Benjamin Purow
and AC Johnson. The following sequences were used for
the production of lentiviruses generating small hairpin
RNA (shRNA): CAGCAGTTTATTACTCACTAA
(Brca1 si1), CAGGAAATGGCTGAACTAGAA (Brca1
si2) and GCTAAACTCGTAATTCAACTT (scrambled
control RNA interference (RNAi)). Transient transfec-
tion of siRNA was performed using siRNA and Hyper-
Fect transfection protocol (QIAGEN, Valencia, CA,
USA) according to the manufacturer’s instructions.
Stably infected cells lines were produced using lenti-
viruses. The sh sequences were cloned into the pLKO.1
vector, and lentiviruses were produced in the 293FT cell
line (Invitrogen, Carlsbad, CA, USA). The cells were
infected and selected with puromycin as previously
described [10].
Flow cytometry
To measure the kinetics of binding of EGF, cells were
grown for 24 hours in 6-cm dishes and serum-deprived
for 4 to 6 hours at 37°C, followed by a 1-hour incuba-
tion on ice with indicated amounts of Rh-EGF. For
uptake and binding, cells were incubated on ice with
10 ng of Rh-EGF, then the excess Rh-EGF was removed
with an ice-cold phosphate-buffered saline (PBS) wash
and the cells were incubated at 37°C for the indicated
time intervals. The reaction was stopped on ice, and the
noninternalized receptor was stripped with a light acid
buffer (50 mM glycine, 150 mM NaCl, pH 3.0). The
cells were gently dissociated with trypsin replacement
TrypLE (Invitrogen, Carlsbad, CA, USA) and resus-
pended in PBS. The ALDEFLUOR assay kit was used to
identify the stem and progenitor cell populations
according to manufacturer’s instructions. BODIPY ami-
noacetaldehyde (BAAA) was used as a substrate, and
diethylaminobenzaldehyde was used as an inhibitor for
negative controls. Cell surface-bound EGFR was mea-
sured using a phycoerythrin (PE)-conjugated EGFR anti-
body and PE-conjugated mouse IgG2b isotype control
antibody. Following gentle cell dissociation or
ALDEFLUOR assay, the cells were washed, resuspended
in 80 μl of PBS with bovine serum albumin (BSA) or
ALDEFLUOR assay buffer and 20 μl of either antibody
or isotype control solution were added. Reactions were
incubated on ice for 30 minutes, the cells were washed
with either PBS and BSA or ALDEFLUOR assay buffer
and resuspended in 0.5 ml of PBS or ALDEFLUOR
assay buffer. QuantiBrite beads were used to estimate
the number of EGFR molecules per cell. Samples were
measured using a FACSAria™ II Cell Sorter 5-laser
SORP instrument (BD Biosciences, San Jose, CA, USA)
or sorted using a MoFlo sorter (Beckman-Coulter, Inc,
Miami FL, USA).
Immunofluorescence
Cells cultured on coverslips for 24 hours were fixed for
10 minutes at room temperature in 3% paraformalde-
hyde/2% sucrose solution, rinsed twice with PBS and per-
meabilized with ice-cold Triton X-100 solution (0.5%
Triton X-100, 20 mM HEPES ((4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid )), pH 7.4, 50 mM NaCl, 3
mM MgCl2, 300 mM sucrose) for 3 minutes on ice. The
cells were rinsed for 5 times with PBS and blocked for
20 minutes with 10% goat serum followed by incubation
with primary antibody anti-EGFR (EGFR.1) and anti-
ALDH1A1 (EP1933Y) for 20 minutes at 37°C. Cells were
washed two times and incubated for 20 minutes at 37°C
with secondary antibody Alexa 488-conjugated anti-
rabbit or Alexa 594-conjugated anti-mouse antibody
(1:1,000 dilution; Invitrogen). The nuclei were stained
with DAPI (1:10,000 dilution; 4’,6-diamidino-2-phenylin-
dole), and the slides were examined using a Nikon
fluorescence microscope (Nikon, Tokyo, Japan). For
quantification of the fluorescence signal, the mean inten-
sity was determined using ImageJ software in four differ-
ent fields for each sample. Experiments were performed
in triplicate, and the means and standard deviations of
the signal intensities were calculated for each condition.
Real-time RT-PCR
Total RNA was extracted using the RNeasy Plus Mini
Kit (QIAGEN). RNA was reverse-transcribed using the
AccuScript enzyme in the AccuScript High Fidelity RT-
PCR System (Agilent Technologies, Stratagene Products
D i v i s i o n ,L aJ o l l a ,C A ,U S A ) . A quantitative real-time
RT-PCR assay was carried out on a Rotor-Gene 6000
cycler (Corbett Life Science, San Francisco, CA, USA)
using SYBR Green Supermix (Bio-Rad Laboratories,
Hercules, CA, USA). The PCR reaction (15 μl) was per-
formed under the following conditions: 95°C for 10 min-
utes followed by 45 cycles at 95°C for 20 seconds, at
56°C for 25 seconds and at 72°C for 40 seconds. The
expression of the EGFR gene was normalized to
GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
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(70 bp) were forward primer 5’-GCACCTACGGATG-
CACTGG-3’ and reverse primer 5’-GGCGATGGACGG-
GATCTTA-3’.
Immunohistochemistry, morphometry and statistics
Immunohistochemistry was performed as described pre-
viously [11]. Scoring for EGFR expression was done
according to the following system: Score 0 no staining
or staining in less than 10% of cells. Score 1+, a faint
perceptible membrane staining can be detected in more
than 10% of cells. Score 2+, a weak to moderate com-
plete membrane staining is observed in more than 10%
of cells. Score 3+, a strong complete membrane staining
is observed in more than 10% of the cells. Colonies
were documented using ACT-1 software connected to
an Olympus SZX12 or a Nikon EclipseS100 microscope
and analyzed using SIGNATURE software [12].
At w o - s i d e dt-test was used to determine statistical
significance. Kaplan-Meier analysis was done using the
GraphPad Prism software package (GraphPad Software,
La Jolla, CA, USA), and survival statistics were calcu-
lated using the log-rank test. Scatchard analysis of Rh-
EGF binding was done as described previously [13,14].
Animal experiments
All animal experiments were conducted in accordance
with Institutional Animal Care and Use Committee-
approved protocols. Experimental female mice, Brca1
flox/
flox,M M T V - C r ea n dp53
+/-, were obtained by breeding
Brca1 conditional knockout mice from the National
Institutes of Health repository (01XC8, strain C57BL/6),
originally generated by Xu et al. [15], who made these
mice available to us via the National Cancer Institute
repository, with MMTV-Cre mice (B6129-TgN(MMTV-
Cre)4Mam; Jackson Laboratory, Bar Harbor, ME, USA)
[16] and p53-knockout mice (P53N12-M, C57BL/6;
Taconic Farms, Germantown, NY, USA) [17]. At the
time of the study, the mice had been inbred for 2 years
(seven generations). The floxed or wild-type status of
Brca1, the presence of the MMTV-Cre transgene and
p53 heterozygosity were determined by PCR as pre-
viously described [15]. Mice were examined for the
occurrence of tumors twice weekly. When tumor
metrics were performed, the length and width of the
tumor were determined using calipers and the tumor
volume was determined by calculating width
2 ×l e n g t h /
2. Tumor growth was recorded as the ratio of tumor
growth to tumor volume at the time of diagnosis.
Results
BRCA1 inhibition results in increased EGFR expression
To examine whether EGFR upregulation is directly
related to the loss of BRCA1, we suppressed BRCA1 in
different MEC lines, including MCF-10A [18], hMEC-
hTERT and HMLE [19]. These MEC lines have not yet
undergone transformation, and instead are propagated
as immortalized cells. hMECs were transfected with
control or BRCA1-directed siRNA and analyzed 72 to
120 hours after transfection. MCF-10A and HMLE cells
showed poor transfection efficiency upon transient
transfection with siRNA, and therefore these cells were
infected with lentiviruses that expressed shRNAi against
BRCA1 (Figure 1A) and selected for pools of infected
cells with puromycin. Asynchronously growing cells
were lysed and analyzed for EGFR expression. Through-
out these experiments, the effects observed after short-
term suppression of BRCA1 with transient transfection
in hMECs were similar to the results obtained in MCF-
10A and HMLE cells with longer-term suppression of
BRCA1 after lentiviral infection and puromycin
selection.
In all three cell lines and with either approach, we
found that EGFR protein levels as measured by immu-
noblotting with anti-EGFR antibodies increased when
BRCA1 was inhibited (Figure 1A). We measured the
density of the immunoblotting signals and found that,
with BRCA1 inhibition, EGFR levels increased by up to
five times over baseline (Figure 1A). In addition, there
appeared to be a tight negative correlation of BRCA1
and EGFR levels (r
2 = 0.87), suggesting a regulatory role
of BRCA1 for EGFR (Figure 1B). Next, we examined
EGFR levels in response to BRCA1 suppression under
conditions of steady-state growth or serum starvation
using immunofluorescence and quantification of the
EGFR fluorescence signal (Figure 1D, bar graph). We
found that BRCA1 inhibition led to EGFR upregulation
under both conditions, as well as asynchronous growth
and starvation, suggesting that the effect of BRCA1 sup-
pression on EGFR expression is not mediated by the
absence or presence of growth factors (Figure 1D).
We then used flow cytometry to examine whether the
increase in total cellular EGFR protein was accompanied
by an increase in EGF binding sites on the cell surface
as opposed to intracellular accumulation. We found that
hMEC-hTERT expressed an average of 6 × 10
3 EGFR
per cell, which increased up to twofold after siRNA inhi-
bition of BRCA1 (Figure 1C). A similar increase of cell
surface EGFR was seen with a second BRCA1-targeted
siRNA (si1) in hMECs and using BRCA1-directed
shRNA in MCF-10A cells (Figures 4G and 4H). Immu-
nofluorescence of EGFR using anti-EGFR antibodies in
hMEC-hTERT confirmed that BRCA1 inhibition
resulted in an increase in both surface and intracellular
EGFR, with a strong increase of EGFR on the cell sur-
face upon serum deprivation after BRCA1 inhibition
(Figure 1D). In summary, we found that both transient
and stable suppression of BRCA1 l e dt oa nu pt o
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Figure 1 BRCA1 suppression in mammary epithelial cells (MECs) leads to an increase in epidermal growth factor receptor (EGFR)
expression. (A) MECs were transfected with BRCA1 control or small interfering RNA 1 or 2 (si1, si2), or they were infected with lentivirus-
expressing control or BRCA1-specific small hairpin RNA (sh1, sh2) and lysed for immunoblot analysis.. (B) The intensities of the
chemiluminescence signals of EGFR, BRCA1 and tubulin levels were quantified using ImageJ software. (C) Flow cytometry using phycoerythrin-
conjugated anti-EGFR antibodies shows an increase in cell surface EGFR expression after BRCA1 suppression (hMEC-hTERT; similar results were
obtained with MCF-10A cells). (D) Immunofluorescence of EGFR in asynchronously growing HMLE (top) and after serum deprivation (bottom) in
control (left) and BRCA1-suppressed MECs (right). Experiments were performed in triplicates using controls and two different small hairpin-
containing MEC lines. (E) The fluorescence intensity of the images was quantified using ImageJ software.
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mately twofold increase in the number of EGFR
expressed on the MEC surface. Thus, the increase in
intracellular EGFR was more pronounced than the
increase in cell surface-expressed EGFR upon BRCA1
inhibition.
BRCA1 inhibition increases EGFR expression through both
an increase in transcription as well as stabilization of the
EGFR protein
We next examined the molecular mechanisms by which
BRCA1 inhibition caused an increase in EGFR protein.
Given earlier reports that BRCA1 can function as a tran-
scriptional regulator and that it specifically regulates
another receptor tyrosine kinase, insulin-like growth fac-
tor I receptor (IGF-IR) [20,21], we analyzed mRNA
levels using quantitative RT-PCR. We found that in
MEC lines with stably suppressed BRCA1 levels, EGFR
mRNA was upregulated 1.5- to twofold in HMLE and
two- to threefold in MCF-10A cells, indicating an
increase in EGFR transcription in response to BRCA1
downregulation (Figure 2A). We next examined the
effects of BRCA1 suppression on EGFR promoter activ-
ity to determine whether the increase in EGFR mRNA
was due to direct transcriptional activation. As these
luciferase assays required transient transfection of
siRNA and reporter plasmid, they could be performed
only in hMECs, not in MCF-10A or HMLE cells. There-
fore, we performed a second set of luciferase assays in
MCF-7 breast cancer cells. We found that EGFR promo-
ter activity increased up to twofold upon BRCA1 sup-
pression (Figure 2B), consistent with the increase in
mRNA levels observed (Figure 2A) and confirming that
BRCA1 exerts a negative regulatory role on EGFR
transcription.
Because BRCA1 also has ubiquitin ligase activity
toward tubulin [22], ERa [23] and phosphorylated Akt
[24], and because we observed a pronounced increase in
intracellular EGFR upon BRCA1 suppression (Figure
1D), we tested whether BRCA1 suppression affects
EGFR stability after blockade of protein biosynthesis
with cycloheximide (Figures 2C and 2D). Interestingly,
BRCA1 suppression increased the half-life of the EGFR
protein from less than 30 minutes to over 75 minutes
(Figure 2D). Thus, there appear to be at least two
mechanisms that result in an increase in EGFR protein
levels upon BRCA1 suppression, transcriptional regula-
tion and protein stabilization.
ALDH1-positive cells show an increase in EGFR expression
Using immunofluorescence imaging, we noted heteroge-
neity with regard to EGFR expression in both control
MECs as well as in MECs after BRCA1 inhibition (Fig-
ures 1D and 3D). An increased expression of EGFR in
basal cells was previously observed in murine MECs
[25] and hMECs [26], and a drift toward high EGFR
expression was seen in cell line models of basaloid
breast cancer [27], which led us to examine whether the
EGFR levels differed between stem and non-stem cells
as defined by the expression of ALDH1 [28,29]. We
found that mean numbers of EGFR were higher in the
ALDH1-positive fractions of MECs than in the ALDH1-
negative fractions. (Figure 3A, top, and Figure 4G). Con-
sistently, ALDH1-positive MECs showed an increased
binding of Rh-labeled EGF when compared to the
ALDH1-negative fraction (Figure 3A, bottom, and
Figures 3B and 3C). Given these differences in cell sur-
face-expressed EGFR, we compared the kinetics of EGF
binding and internalization between ALDH1-positive
and ALDH1-negative MECs. For the binding assay, cells
were incubated with increasing concentrations of Rh-
labeled EGF, and binding was analyzed using flow cyto-
metry (Figure 3B). Scatchard analysis of Rh-EGF binding
at 4°C showed that both the ALDH1-positive and
ALDH1-negative population bound EGF with similar
affinity (Kd = 0.32 nM) (Figure 3B, inset). For binding
and internalization (Figure 3C), cells were preincubated
with Rh-EGF at 4°C to allow for binding, followed by
removal of unbound Rh-EGF incubated for the indicated
times and concentrations with Rh-labeled EGF at 37°C,
and then washed with either PBS or an acidified buffer
as described previously [30], followed by ALDH1 stain-
ing. While the PBS wash removes only unbound Rh-
EGF, the acidified buffer removes both receptor-bound
and receptor-unbound EGF, that is, fluorescence after
the acidic wash is representative of internalized EGF.
We found that EGF binding was biphasic, both in
ALDH1-positive and ALDH1-negative cells, with an
initial saturation of EGF binding sites after 5 minutes,
followed by a second, slower phase of binding and inter-
nalization. Internalization was complete after 30 minutes
at 37°C (Figure 3C).
In summary, binding and internalization kinetics were
similar in ALDH1-positive and ALDH1-negative MECs,
while the total number of circulating EGF receptors was
increased in the ALDH1-positive fraction.
BRCA1 inhibition increases EGFR expression in both the
ALDH1-negative and the expanded ALDH1-positive cell
pool
The heterogeneity of the MEC pool, and how this het-
erogeneity is affected by the loss of BRCA1, is an area of
active research [29,31]. Several immunophenotype pro-
files have been used to define MEC progenitor cells,
such as the CD24
low/CD44
high profile [32] and the
CD49f
+/EpCam
+ profile [31]. Consistent with the data
published by Liu et al. [29] and with our own observa-
tions in BRCA1 mutation carriers [11], we found that
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Figure 2 Transcriptional and posttranslational mechnisms lead to an in crease in EGFR expression after BRCA1 inhibition. (A) EGFR
mRNA levels were determined in control MECs (light gray bars) and in mammary epithelial cells (MECs) expressing small hairpin RNA directed
against BRCA1 (dark bars). RNA levels were normalized for GAPDH (glyceraldehyde 3-phosphate dehydrogenase) expression. RT-PCR, real-time
reverse transcriptase-polymerase chain reaction; HMLE, human mammary epithelial cells. (B) Decreased EGFR promoter activity as a result of
short-term BRCA1 suppression in MECs and MCF-7 cancer cells. BRCA1 control and small interfering RNA (siRNA) and the full-length EGFR
promoter were transfected as indicated, and luciferase activity was normalized for Renilla thymidine kinase expression. (C and D) EGFR half-life
increases from less than 30 minutes to over 70 minutes after BRCA1 inhibition. Control and BRCA1 sh2-expressing MCF-10A cells were transfected
with hemagglutinin-tagged EGFR 48 hours prior to the time course, serum-deprived for 8 hours, then treated with cycloheximide at 100 μg/ml
for 2 hours, and stimulated with epidermal growth factor at point 0. Lysates were prepared and immunoblotted at the indicated time points.
The chemiluminescence signal was quantified as in Figure 1B. Similar results were obtained with BRCA1 sh1-expressing cells. In D the ratio of
the optical density (OD) for EGFR to Tubulin is plotted against time.
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Page 7 of 18the percentage of ALDH1-positive cells increased four-
fold in hMEC-hTERT and doubled in MCF-10A cells in
response to inhibition of BRCA1 (Figures 4C and 4F). In
addition, we found a corresponding increase in the
CD24
low/CD44
high population in both HMLE and MCF-
10A cells expressing BRCA1 shRNA (Additional file 1,
Figure S1), thus confirming an increased MEC progenitor
cell pool in response to BRCA1 inhibition [29,32]. Using
two-color flow cytometry and QuantiBrite beads [33], we
found that ALDH1-positive MECs carried two to three
times the number of EGF receptors compared with
ALDH1-negative cells (Figures 3A, 4G and 4H). Upon
BRCA1 inhibition with siRNA in hMECs or with shRNA
in MCF-10A cells, a significant increase of EGFR was
observed in ALDH1-negative and ALDH1-positive MECs
(Figures 4G and 4H, dark bars). Thus, our data show that
BRCA1 inhibition affects EGFR expression in two ways:
BRCA1 suppression leads to the expansion of the highly
EGFR-expressing ALDH1-positive MEC pool (Figures 4C
and 4F through 4H), and, second, BRCA1 inhibition
raises the numbers of EGF receptors per cell in all MECs
(ALDH1-positive and ALDH1-negative cells), likely
through transcriptional activation (Figure 2A) and post-
translational mechanisms (Figure 2B).
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Figure 3 Heterogeneity and kinetics of epidermal growth factor receptor (EGFR) expression in mammary epithelial cells (MECs).
(A) Dual staining of aldehyde dehydrogenase 1 (ALDH1)-positive cells (green fluorescence) with anti-EGFR antibodies (top) or rhodamine (Rh)-
labeled epidermal growth factor (EGF) (bottom) in human MEC-human telomerase reverse transcriptase (hMEC-hTERT). Negative controls used to
adjust compensation settings are shown (left). ALDH1-positive cells show higher EGF binding and a higher number of EGF receptors (right).
DEAB, diethylaminobenzaldehyde. (B) Binding of EGF in ALDH1-negative or ALDH1-positive MECs. Cells were incubated at 4°C with the indicated
amounts of EGF and labeled with ALDH1 reagent. Inset: Scatchard analysis of EGF binding. Kd values were 0.32 nM for both the ALDH1
+ and
ALDH1
- fractions. The intensity of the red fluorescence was measured using the channel for red fluorescence (Discosoma Red - ds-red) of the
flow cytometer. (C) EGF binding and uptake. Cells were incubated with 10 ng/ml Rh-EGF at 4°C, free Rh-EGF was removed and MECs were
counterstained with ALDH1 reagent. To assess binding and uptake, cells were washed with phosphate-buffered saline (PBS) (solid symbols). To
assess solely uptake, bound EGF was removed using an acetic acid wash (bordered symbols). (D) Immunofluorescence of EGFR and ALDH1 in
aysynchronously growing MECs (human MEC-human telomerase reverse transcriptase).
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expressing control or BRCA1 small hairpin RNA (shRNA). Cells treated with the ALDH1 inhibitor diethylaminobenzaldehyde (DMEA) served as
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with ALDH1 reagent followed by immunostaining with phycoerythrin (PE)-conjugated anti-EGFR antibodies and quantification of EGFR using the
QuantiBrite standards for PE.
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Page 9 of 18EGFR inhibitor erlotinib blocks the outgrowth of normal
and BRCA1-deficient MECs
Given our findings of EGFR upregulation in MECs upon
BRCA1 inhibition, as well as our previous findings of
altered growth and differentiation patterns of EGFR-
expressing MECs isolated from BRCA1 mutation car-
riers [8], we asked whether EGFR inhibition could block
this phenotype. First, we examined the growth charac-
teristics of control and BRCA1-suppressed or BRCA1-
mutant MECs. Consistent with our previous data, we
found that after experimental suppression of BRCA1,
MECs formed larger colonies with greater efficiency
than control cells in the three-dimensional Matrigel-
based cultures (Figures 5A and 5B). Similar findings
were obtained with primary MECs from BRCA1 muta-
tion carriers, which yielded a higher number of larger
colonies than controls (Figure 5C) [8]. Finally, our
results were further confirmed by MEC cultures from
MMTV-Cre BRCA1
flox/flox mice, in which even the het-
erozygote loss of BRCA1 led to increased clonality of
MECs (Figure 6B). Thus, our data in primary hMECs,
murine MECs and immortalized MECs with experimen-
tal BRCA1 suppression all confirm that even partial sup-
pression or heterozygote loss of BRCA1 causes an
increase in the clonogenicity and proliferative potential
of MECs.
Next, we treated MECs with the EGFR inhibitor erlo-
tinib and found that erlotinib efficiently blocked the out-
growth of colonies from all MECs, controls as well as
BRCA1-suppressed MECs (Figures 5A and 5B), of nor-
mal and BRCA1-mutant primary MECs (Figure 5C), as
well as of murine MECs that were wild-type or BRCA1-
deficient (Figure 6C). In dose-response experiments, we
found that <1 μM erlotinib was sufficient to suppress
MEC outgrowth in both hMECs (Figure 5D) and murine
MECs (Figure 6C), indicating that MECs carrying a
wild-type EGFR are highly sensitive to the growth-
inhibitory effect of erlotinib. In addition, we used a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT)-based cell viability assay to determine the
effects of erlotinib on MEC growth. Cells were seeded at
equal densities, and cell viability was measured daily
over a period of 7 days (Figure 5E). This quantitative
cell viability assay confirmed that both cell types that
expressed BRCA1-inhibitory shRNA grew significantly
faster and reached double the cell number after 7 days
of culture compared to controls (Figure 5E), thus con-
firming that loss of BRCA1 leads to accelerated prolif-
eration of MECs. In the quantitative cell viability assay,
MECs with loss of BRCA1 were equally as sensitive to
erlotinib as wild-type cells (Figure 5E), confirming our
observations in the colony formation assays (Figures 5A
t h r o u g h5 Da n dF i g u r e6 ) .I ns u m m a r y ,b o t hr e a d o u t
methods, colony formation assay as well as cell viability
assay, confirmed that MECs with loss of BRCA1 that
express higher EGFR levels proliferate more rapidly than
controls and that this increase in proliferation remains
highly sensitive to the growth-inhibitory effect of
erlotinib.
MECs from BRCA1-mutant mice show proliferation and
differentiation patterns similar to MECs from human
BRCA1 mutation carriers
The model of MMTV-Cre flox-directed deletion of
BRCA1 was first developed by Xu et al. [15] and has
been used extensively to examine BRCA1-related tumor-
igenesis. When grown in three-dimensional Matrigel-
based cultures, murine MECs grew in patterns similar
to those of hMECs, that is, cells from wild-type mice
formed hollow acini after 10- to 14-day culture periods
(Figure 6A, top). In cells isolated from MMTV-Cre
BRCA1
flox/flox p53
+/- mice, we found large, complex,
solid structures (Figure 6A, bottom), similar to those
that we found in human BRCA1 mutation carriers [8].
Next, we examined the mammary gland tissues of five
MMTV-Cre BRCA1
flox/flox p53
+/- mice and seven Cre-
negative, age-matched control mice for the expression
of EGFR and ALDH1 (Figure 6C). We found that the
mammary glands of BRCA1-mutant mice in general
contained more acini than the controls. In each of the
MMTV-Cre BRCA1
flox/flox p53
+/- mammary glands, we
found entire acini that stained positive for both EGFR
and ALDH1, while only occasional single cells were
positive in any of the Cre-negative control glands.
MMTV-Cre BRCA1
flox/flox p53
+/- mice develop breast
cancer with a latency of about 8 to 10 months, while
MMTV-Cre BRCA1
flox/flox mice develop tumors with
relatively low penetrance beyond age 1 year or older
[34], and MMTV-Cre BRCA1
flox/wt mice rarely develop
spontaneous breast cancers. Therefore, we examined the
clonogenicity of murine MECs that had not yet formed
tumors at age 7 months for MMTV-Cre BRCA1
flox/flox
p53
+/- mice and at age 12 months for MMTV-Cre
BRCA1
flox/flox or MMTV-Cre BRCA1
flox/wt. In compar-
ison to wild-type cells, all three mutant cell types
showed significantly increased colony formation (Figure
6B). Interestingly, this increase in clonogenicity was
observed not only in cells from mice with homozygotic
loss of BRCA1 but also in cells from mice with hetero-
zygotic loss of BRCA1 (MMTV-Cre BRCA1
flox/wt),
indicating that loss of a single allele, which is a situation
analogous to a human BRCA1 mutation carrier, leads to
an increase in colony formation (Figure 6B).
Next, we examined whether treatment with erlotinib
was similarly effective in murine MECs as it was in
hMECs, and we found that colony formation was
suppressed effectively at 1 μM erlotinib in the medium
(Figure 6D). On the basis of these findings, we tested
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Figure 5 BRCA1 inhibition leads to increased colony formation and size that is completely blocked by epidermal growth factor
receptor (EGFR) inhibition. Mammary epithelial cells (MECs) expressing either (A and B) control small hairpin RNA (shRNA) or BRCA1-directed
shRNA or (C and D) primary MECs isolated from reduction mammoplasties or BRCA1 mutation carriers were seeded and photographed after 10
days in culture. All colony formation was completely suppressed when cells were grown in the presence of erlotinib at 2 μM shown in phase
images for each cell type (right). (D) MEC growth is inhibited at concentrations as low as 0.5 μM erlotinib. Cells were seeded at 5,000 cells/well,
allowed to grow for 10 days in the presence of the indicated amounts of erlotinib and then counted. (E) Cell viability assay of control and
BRCA1 shRNA-expressing human MECs. Cells were seeded in triplicate in 96-well plates at 250 cells/well, and cell viability was determined daily.
Dotted line and open symbol represent control cells, and closed symbols represent cells expressing BRCA1-directed shRNA. Black lines, vehicle
control; blue lines, culture in the presence of 2.5 μM erlotinib; red line, culture in the presence of 5 μM erlotinib.
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Page 11 of 18the efficacy of erlotinib for the primary prevention of
breast cancer in BRCA1-mutant mice.
EGFR inhibitor erlotinib prevents the development of ER-
negative, but not of ER-positive, breast cancers in BRCA1-
mutant mice
Starting at age 3 months, MMTV-Cre BRCA1
flox/flox
p53
+/- mice were treated with either the EGFR inhibitor
erlotinib at 100 mg/kg/day orally (treatment cohort) or
vehicle control (control cohort) as dosed previously [35].
End points were tumor-free survival and tolerability of
the prophylactic erlotinib treatments. The mice tolerated
the treatments well, with theo n l ya d v e r s ee f f e c tb e i n g
partial alopecia in about 30% of the mice. Mice were
examined daily, and tumors were diagnosed by palpa-
tion. Upon necropsy, tumors were counted, fixed and
examined for ER expression. Survival analysis (Figure 7)
showed a median disease-free survival of 365 days in the
erlotinib-treated cohort versus 256 days in the control
cohort, that is, erlotinib treatments delayed tumor devel-
opment by an average of 3 months. Only 19 tumors
were observed in the erlotinib-treated cohort versus 31
tumors in the control cohort, a significant reduction (P
= 0.0003). Upon necropsy, tumors were fixed and pro-
cessed for immunohistochemistry (Table 1 and Addi-
tional file 2, Figure S2). As expected on the basis of
previous studies [34,36], the mice in the control cohort
developed both ER-positive and ER-negative breast
cancers, with a predominance of ER-negative tumors.
Interestingly, while the number of ER-positive tumors
was not significantly different in both cohorts, the num-
ber of ER-negative breast cancers was sharply reduced
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Figure 6 Proliferation and differentiation properties of MECs from MMTV-Cre BRCA1-mutant mice . (A and B) Growth and proliferation
properties of mammary epithelial cells (MECs) isolated from mouse mammary tumor virus-Cre recombinase (MMTV-Cre) BRCA1-mutant mice are
similar to MECs isolated from human BRCA1 mutation carriers. MECs were harvested and plated as described previously [8]. (A, top) Cultures
from wild-type (WT) control mice resulted in round acinar structures, whereas (A, bottom) cultures from MMTV-Cre BRCA1
flox/flox p53
+/- mice
showed complex and irregular features. (B) The overall colony-forming efficiency of murine BRCA1-mutant MECs is increased. Non-tumor-bearing
WT and MMTV-BRCA1
flox/flox p53
+/- MECs were compared at age 7 months, and non-tumor-bearing mice from MMTV-Cre BRCA1
flox/WT
(heterozygous loss of BRCA1) MMTV-Cre BRCA1
flox/flox were compared at age 12 to 13 months. (C) Mammary glands from MMTV-Cre BRCA1
flox/
flox p53
+/- mice contain epidermal growth factor receptor (EGFR) and aldehyde dehydrogenase 1 (ALDH1)-positive acini. Immunohistochemistry
for EGFR and ALDH1 was performed on five BRCA1-mutant mammary glands and seven Cre-negative controls. Representative images are shown
at × 20 original magnification. (D) Erlotinib is active in suppressing the growth of murine MECs from mice of WT, MMTV-Cre BRCA1
flox/flox or
MMTV BRCA1
flox/flox p53
+/- background. All MECs were seeded in Matrigel-based cultures and photographed and analyzed for colony formation
using SIGNATURE software [12] after 14 days of culture.
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Figure 7 Erlotinib as a chemopreventative agent in (MMTV-Cre) BRCA1
flox/flox p53
+/- mice. (A) Erlotinib prevents the emergence of
estrogen receptor-negative (ER
-) but not estrogen receptor-positive (ER
+) breast cancers in mouse mammary tumor virus-Cre recombinase
(MMTV-Cre) BRCA1
flox/flox p53
+/- mice. Virgin female mice were treated as controls or with 100 mg/kg erlotinib via oral gavage once daily, seven
days per week. Tumors were recorded when they were first palpated. Kaplan-Meier graphing and analysis of disease-free survival were
performed using the GraphPad Prism software package. (B) The growth of established breast cancers is not affected by erlotinib treatment. Mice
that developed tumors in the control cohort were switched to erlotinib treatment, and the tumor volume relative to the tumor volume at
diagnosis was plotted against treatment time. ER status was determined after necropsy. The trend line for vehicle control-treated tumors was
established on the basis of the tumor volumes of control mice.
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Page 13 of 18in the erlotinib-treated cohort (n =5v e r s u sn = 19,
respectively), indicating that erlotinib was effective in
preventing the emergence of ER-negative, but not ER-
positive, breast cancers in this mouse model (Table 1).
Importantly, EGFR staining showed that the erlotinib-
treated cohort had a much lower number of EGFR-posi-
tive tumors than the control group, again confirming
that erlotinib treatments selected for EGFR-negative
tumors (Table 1). ALDH1 staining was observed in
nests and at the edges of the tumors in clusters (Addi-
tional file 2, Figure S2) and was highly variable among
tumors. There was a trend toward lower ALDH1
expression in the erlotinib-treated cohort; however,
given the high variability of ALDH1 expression, statisti-
cal significance was not reached. The Ki-67 labeling
index as a marker for proliferation [37] was also highly
variable between tumors and did not differ significantly
between the erlotinib-treated and control cohorts,
although there was a trend toward higher Ki-67 expres-
sion in control tumors (Table 1). The cell death index
as assessed by cleaved caspase 3 expression [37] was less
variable, and we found a higher cell death index in the
erlotinib-treated cohort than in controls, possibly indi-
cating that a fraction of the tumor cells still responded
to EGFR inhibition while the majority of tumor cells
were resistant. Finally, we examined whether erlotinib
had any effect on the growth of established tumors in
this mouse model (Figure 7B). Tumor metrics showed
that once tumors were established, erlotinib did not
shrink these tumors, and tumors grew similarly to the
vehicle control-treated tumors. The lack of efficacy of
erlotinib on established tumors was seen in ER-negative
and ER-positive tumors, further confirming that EGFR
inhibition prevented the emergence of ER-negative
tumors but likely did not kill nascent ER-negative
tumors. In summary, we found that tumors that
emerged in erlotinib-treated mice tended to be positive
for ER and negative for EGFR and ALDH1. Once
tumors were established, their growth was not delayed
by treatments with erlotinib, indicating that the majority
of tumor cells are resistant to erlotinib treatment and
grow independently of EGFR signaling.
Discussion
Haploinsufficiency phenotype of BRCA1 includes
enhanced proliferation of MECs
We previously found that that the nonmalignant MECs
from BRCA1 mutation carriers contain a subpopulation
of progenitor cells with significantly increased clonal
and proliferative potential compared with normal con-
trols [8]. Of these cells, 79% had not undergone loss of
heterozygosity but had remained heterozygous for
BRCA1 (retention of heterozygosity), and these cells
tended to differentiate into ER-negative, EGFR-positive
colonies compared to controls. Our observations con-
firm that even partial loss of BRCA1 leads to an increase
aM E C s ’ clonal proliferation (Figures 5 and 6), lending
further support to the concept that haploinsufficiency of
BRCA1 with reduced protein levels of BRCA1 leads to a
differentiation block coupled with enhanced prolifera-
tion of MECs [8,38].
BRCA1 wt and BRCA1-haploinsufficient MECs depend on
EGFR for proliferation
MECs rely on EGFR activation for migration, prolifera-
tion and survival of mammary epithelial progenitor cells.
However, the role that EGFR plays in either the initia-
tion or the maintenance of the malignant phenotype is
largely unknown. Regardless of whether the progenitor
cell population expanded through the loss of BRCA1 is
defined by expression of ALDH1 [8,29] or Epcam
+/CD49
+ [31], the progenitor cell population expanded
Table 1 Clinicopathologic features of observed tumors in erlotinib-treated prevention cohort and controls
a
Clinicopathologic features Erlotinib (N = 13) Control (N = 14) P value
Median disease-free survival, days 365 256 0.0001
Number of tumors 19 31 0.0003
ER-positive tumors 14 12 n.s.
ER-negative tumors 5 19 0.0000002
EGFR
b 0.0004
01 0 3
1+ 6 8
2+ 0 6
3+ 0 2
Mean ALDH1
b, % (±SD) 3.8% (2.8%) 9.0% (9.8%) 0.11 (n.s.)
Mean Ki-67
b, % (±SD) 21.4% (14%) 30.4% (17.7%) 0.6 (n.s.)
Mean cleaved caspase 3
b, % (±SD) 18.4% (8.6%) 10.6% (8.4%) 0.018
aER, estrogen receptor; n.s., not significant; EGFR, epidermal growth factor receptor; ALDH1, aldehyde dehydrogenase 1; SD, standard deviation;
bonly 16 tumors
in the erlotinib-treated cohort and 19 tumors in the control cohort could be processed for EGFR, ALDH1, cleaved caspase 3 and Ki-67. A two-sided t-test was
performed to analyze statistical significance.
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sion relative to the control cells [8,31]. Here we show
that suppression of BRCA1 leads directly to an increase
in EGFR expression with increased clonal growth of
MECs (Figure 5), which can be entirely suppressed by
the EGFR inhibitor erlotinib (Figures 5 to 7), suggesting
that while loss of BRCA1 l e a d st oa ni n c r e a s ei nE G F R
activity, loss of BRCA1 does not convey growth factor
independence.
Multiple mechanisms contribute to the BRCA1-related
increase in EGFR expression
A direct regulatory role of BRCA1 for the transcription of
a receptor tyrosine kinase has been reported for the IGF-
IR gene [20,21,39]. Abramovitch et al. [17] and Maor
et al. [18] found that IGF-IR and IGF-IIR mRNA expres-
sion levels are elevated in the tissues of women with a
genetic predisposition to breast cancer. They showed that
BRCA1 interacts with and prevents the binding of the
specificity protein 1 (Sp1) transcription factor to the IGF-
IR receptor. Sp1 is a general transcription factor with a
wide range of target promoters, with EGFR being among
them [40]. Our data show that downregulation of BRCA1
directly increased EGFR mRNA as well as EGFR promo-
ter activity, suggesting transcriptional regulation (Figures
2A and 2B). Whether the regulation of EGFR transcrip-
tion is also mediated by binding of BRCA1 to Sp1 is cur-
rently unclear. In addition, we have shown a
posttranslational effect of BRCA1 on EGFR protein stabi-
lity (Figures 2C and 2D). The fact that two independent
mechanisms converge to increase cellular EGFR levels
after BRCA1 inhibition suggests the functional impor-
tance of this regulatory axis. BRCA1 levels fluctuate
throughout the cell cycle, and they are highest during the
S phase and mitosis [41]. Downstream signaling from
EGFR, however, is tightly suppressed during mitosis, as
tyrosine phosphorylation of EGFR is highest in the G0/G1
phase, then gradually decreases during the S and G2
phases and reaches its lowest levels during the M phase
[42]. Negative regulation of EGFR by BRCA1 would
ensure the temporal separation between phases when
demand for mitogenic signaling is high, that is, G0/G1,
and between phases when mitogenic signaling might
interfere with DNA synthesis and repair, that is, the S
phase. Such regulatory loops might be dysfunctional in
MECs that have lost one or both alleles of BRCA1, allow-
ing for an increase in mitogenic signaling of MECs with
inherent genetic instability and increased vulnerability to
oncogenic transformation. In this scenario, the primary
effects of loss of BRCA1, that is, an increase in genetic
instability, would cooperate with the secondary effect, an
increase in EGFR signaling, toward proliferation and
eventual transformation of cells with increased genetic
instability.
This BRCA1-EGFR cooperation concept could poten-
tially be broadly applicable to mitogenic signaling and
might explain why not only EGFR but also IGF-IR [43]
is increased in MECs that have lost BRCA1. It may also
explain why BRCA1 has a negative regulatory effect on
the stability of phosphorylated Akt [24] and attenuates
extracellular signal-regulated kinase activation in
response to estrogen or EGF stimulation [44,45]. The
hypothesis that even heterozygotic loss of BRCA1 may
allow for an increase in mitogenic signaling and thereby
convey a growth advantage to MECs with genetic
instability is further supported by the fact that BRCA1
mutation carriers have a strikingly high frequency of
atypical ductal hyperplasia (38% in BRCA1 carriers ver-
sus 4% in control tissues) and ductal carcinoma in situ
(13% in BRCA1 carriers versus none in control tissues)
[46], which most often is negative for ER and positive
for EGFR [47].
EGFR inhibition is effective for the prevention but not for
the treatment of BRCA1-related breast cancers
The expression of EGFR in breast cancer has been
linked to endocrine resistance and poor outcomes
[48-50]. It has also been postulated that EGFR activation
may be an important step in the progression to estrogen
independence [51]. EGFR overexpression appears to cor-
relate with the basaloid phenotype and is found in 67%
of BRCA1-related cancers versus only 18% of non-
BRCA1-related breast cancers [6]. These findings have
prompted the launching of several clinical trials to
examine the therapeutic efficacy of the EGF inhibitors
gefitinib and erlotinib in ER-negative breast cancer.
Early outcome data do not point toward major activity
of EGFR inhibitors in unselected patients with meta-
static breast cancer [52]. Similarly, presurgical exposure
studies have shown only modest or no activity of erloti-
nib on the proliferative index of TNBCs [53]. Our stu-
dies confirm that while erlotinib prevents the emergence
of TNBCs, manifest breast tumors grow independently
of EGFR signaling (Figure 7B).
EGFR inhibition prevents the emergence of ER-negative
but not of ER-positive breast cancers in BRCA1-mutant
mice
Currently, there is a lack of nonsurgical primary preven-
tion options for women at risk for TNBC. Our data
show that the EGFR inhibitor erlotinib was effective in
the prevention of EGFR
+/ER
- breast cancers, but not
EGFR
-/ER
+ breast cancers, in BRCA1-mutant mice (Fig-
ure 7 and Table 1). We have thereby demonstrated for
the first time the principle that EGFR inhibition is effec-
tive in preventing BRCA1-related tumors. The concept
of breast cancer prevention through EGFR inhibition
has been explored previously; in fact, EGFR inhibitors
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cancer in experimental mouse models [54-57]. However,
these mice were BRCA1-proficient and at risk for breast
cancer because of overexpression of transgenic erbB2
(Her2), which is a member of the EGFR family and a
direct target for the drugs used in those studies, that is,
lapatinib or gefitinib. However, in humans, erbB2 ampli-
fication is the result of a somatic mutation. Thus, it is
currently not possible to identify women at risk for the
development of Her2-positive breast cancer, thereby
limiting the applicability of these data. On the other
hand, there is a need to develop medicinal therapeutic
strategies for the prevention of TNBC, especially in
BRCA1 mutation carriers, and our mouse model data
suggest that targeting the EGFR pathway might be pro-
mising. While erlotinib has a relatively benign toxicity
profile, the expected dermatological complications [58]
and unknown long-term effects will likely still make it
prohibitive to use this particular drug for preventive
purposes without time limits. An as yet unsolved ques-
tion is whether a shorter, limited time period of EGFR
inhibition would be protective beyond the actual treat-
ment time, and we are planning to address this issue in
this mouse model. However, as increasingly naturally
occurring compounds that suppress EGFR signaling are
discovered, substances such as allophycocyanins might
hold promise for use as chemopreventive agents [59,60].
Our studies suggest that the window of opportunity for
effective breast cancer prevention using EGFR inhibitors
is a state at which loss of BRCA1 and gain of EGFR
have occurred, but the growth factor independence of
cancer cells has not yet been established.
Conclusions
We have identified a cooperative effect of loss of BRCA1
with gain of EGFR expression that leads to increased
clonal proliferation of MECs and may render these cells
vulnerable to malignant transformation. This coopera-
tive effect is achieved by transcriptional upregulation as
well as posttranslational stabilization of EGFR upon
BRCA1 downregulation. In addition, cells with loss of
BRCA1 are enriched for the highly EGFR-expressing
ALDH1-positive population. The tumorigenic effect of
the cooperation of loss of BRCA1 with gain of EGFR in
nonmalignant MECs can be disrupted by the preventive
use of the EGFR inhibitor erlotinib. Thus, at the prema-
lignant stage, EGFR inhibition may provide a window of
opportunity for breast cancer prevention.
Additional material
Additional file 1: Figure S1. Loss of BRCA1 leads to an increase in the
CD24
lowCD44
high stem cell population in mammary epithelial cells
(MECs). MCF-10A or human MEC (HMLE) cell lines expressing either
control or BRCA1-inhibitory small hairpin (shRNA) constructs were
examined for CD24 and CD44 expression using dual color flow
cytometry. Gates were set using isotype controls for the respective
antibodies. Note that the increase in CD24 and loss of CD44 were more
pronounced in HMLE cells than in MCF-10 cells. However, in both cell
lines, inhibition of BRCA1 led to a notable increase in CD24
lowCD44
high
cells (from 1.1% (control) to 3.8% (sh1) and 8% (sh2) in MCF-10 cells and
from 2.6% (control) to 9.2% (sh1) and 11.6% (sh2) in HMLE cells,
respectively).
Additional file 2: Figure S2. Immunohistochemistry of tumors in the
erlotinib prevention cohort or controls. Aldehyde dehydrogenase 1
(ALDH1) staining tended to be cytoplasmic and to occur in nests and
clusters of cells, as well as at the edges of tumors. Epidermal growth
factor receptor (EGFR) staining was seen at the cell membrane and to
some extent in the cytoplasm. Estrogen receptor and Ki-67 staining were
nuclear, and anti-cleaved caspase 3 antibodies stained cells entirely.
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